SLU-PP-332 vs Cardarine: Which Works Better in 2026?

The phrase "exercise in a pill" has been discussed for two decades, but two investigational compounds have generated particular scientific interest: Cardarine (GW-501516) and the newer SLU-PP-332. The discussion around SLU-PP-332 vs Cardarine is largely academic — it's a question about which mitochondrial pathway researchers are exploring as a target related to fat metabolism, endurance, and body composition. This guide outlines the mechanisms, the preclinical literature, and the practical differences between these two investigational compounds for informational purposes only.

SLU-PP-332 vs Cardarine: At a Glance

What SLU-PP-332 Is

SLU-PP-332 is a synthetic small molecule developed by researchers at Saint Louis University as a pan-agonist of the three estrogen-related receptors: ERRα, ERRβ, and ERRγ. Despite the name, ERRs don't actually bind estrogen — they're orphan nuclear receptors that act as regulators of mitochondrial gene expression, oxidative phosphorylation, and fatty acid metabolism. In preclinical research, activation of these receptors has been reported to influence the same transcriptional program associated with endurance exercise in skeletal muscle.

In preclinical (animal and cell) models, SLU-PP-332 has been reported to influence running endurance, fat oxidation, and metabolic gene expression. The mechanism is upstream of the PPARδ pathway and works through a different transcriptional axis, which is why it has attracted research attention. SLU-PP-332 is an investigational compound with no established human safety data; it is not an approved drug and is not a recognized consumer wellness ingredient.

What Cardarine (GW-501516) Is

Cardarine, or GW-501516, was developed in the 1990s by GlaxoSmithKline and Ligand Pharmaceuticals as an investigational selective PPARδ agonist. PPARδ is a nuclear receptor expressed in skeletal muscle and adipose tissue. In preclinical research, activation has been associated with changes in genes involved in fatty acid transport, beta-oxidation, and mitochondrial efficiency.

Early clinical research with Cardarine reported changes in certain lipid and endurance markers. However, long-term rodent toxicology studies revealed adverse findings with high-dose, long-duration administration. GSK halted development in 2007, and the World Anti-Doping Agency (WADA) added it to its prohibited list shortly after. It remains available only through unregulated channels and carries documented preclinical findings that should be discussed with a qualified physician.

Key Differences Between SLU-PP-332 and Cardarine

• Receptor target: SLU-PP-332 is reported to activate ERRα/β/γ (estrogen-related receptors), while Cardarine targets PPARδ. Different transcription factors, with some overlapping downstream effects on fat metabolism in preclinical models.
• Available data: Both compounds are investigational. SLU-PP-332 is newer and has limited published data overall; Cardarine has more historical data, including the rodent toxicology findings that ended its development. Neither has an established human safety profile suitable for general consumer use, and direct safety comparisons are not appropriate.
• Half-life and dosing: Cardarine has a roughly 24-hour half-life in published reports. SLU-PP-332 has a much shorter half-life. Any use of either compound should be individualized and determined by a qualified physician.
• Regulatory status: Cardarine is on the WADA prohibited list and was pulled from regulated pharmaceutical development. SLU-PP-332 remains an investigational research compound.
• Mechanistic breadth: ERR activation engages transcriptional networks including mitochondrial biogenesis pathways in preclinical work, while PPARδ activation is more narrowly associated with fatty acid handling gene expression.
• Stack compatibility: Because the two compounds work on independent pathways, they are sometimes discussed together in research contexts — but combining investigational compounds is not advisable outside of medical oversight.

The Mitochondrial Pathway Question: ERRα vs PPARδ

The deeper story behind the ERRα agonist vs PPARδ agonist discussion is about which transcriptional lever is being studied inside the mitochondrion. PPARδ functions in preclinical models as a fuel-switching transcription factor — associated with cellular preference for fatty acids over glucose. ERRα, by contrast, is described in the literature as a regulator of mitochondrial biogenesis that works in partnership with PGC-1α, a coactivator upregulated by endurance training in research models.

By engaging all three ERR isoforms, SLU-PP-332 has been reported in preclinical research to influence a transcriptional fingerprint associated with sustained aerobic training. Whether this preclinical pattern translates to humans remains an open research question.

Safety Considerations

Cardarine's development history includes rodent toxicology data in which adverse tissue findings were reported across multiple organs at high doses over long durations. Whether those doses and exposure windows are relevant to lower-dose human use remains debated, but the data was significant enough to halt human development. Anyone considering Cardarine should weigh that documented history and discuss it with a qualified physician.

SLU-PP-332 is much newer and has a very limited safety dataset. The absence of long-term human data is itself an important limitation. Because SLU-PP-332 is an investigational research compound rather than an approved drug or established consumer wellness ingredient, any use should be approached only under qualified medical guidance. Source quality, manufacturing standards, and physician oversight matter more here than in most product categories.

How to Think About These Compounds in 2026

SLU-PP-332 represents a newer investigational pathway with limited published data and no established human safety profile. Any decision to use it should involve a qualified physician familiar with your individual health history.

Cardarine has a longer research history that includes adverse findings in long-term rodent toxicology studies, leading to discontinuation of its clinical development and its placement on the WADA prohibited list. Anyone considering it should review that history with a physician.

Consult a physician first if you have any personal or family history of significant health conditions, are on prescription medications, are pregnant or nursing, or have not yet optimized the fundamentals (training, sleep, protein intake, recovery). Investigational exercise mimetics are not a substitute for foundational habits.

Sourcing and Quality Considerations

Sourcing is where unregulated channels create real risk. Underdosed, contaminated, or mislabeled products are common in the investigational compound category. For SLU-PP-332 specifically, the novelty of the compound makes manufacturing precision and quality verification especially important.

DrSeinfeld.com offers SLU-PP-332 Tablets manufactured to GMP standards with consistent tablet-to-tablet quality. DrSeinfeld.com does not stock Cardarine. Decisions about whether either compound is appropriate for you should be made in consultation with a qualified physician.

Reviewed by Dr. Amy Seinfeld, D.O. This article is educational and is not medical advice. SLU-PP-332 and Cardarine are investigational research compounds, not approved drugs or established consumer wellness ingredients. Always consult your physician before considering any investigational compound. Appropriate dosing and suitability are individualized and should be determined by a qualified healthcare provider.